CardioExchange Archive

September 18th, 2013

Is Edoxaban the Most Promising of the Novel Anticoagulants?

Samuel Goldhaber, MD

Samuel Z. Goldhaber offers his perspective on the Hokusai-VTE randomized trial comparing edoxaban and warfarin in patients with symptomatic venous thromboembolism.

---

September 12th, 2013

Aspirin Therapy with Anticoagulation in Patients with Afib?

Benjamin A. Steinberg, MD and John Ryan, MD

An interview with Benjamin Steinberg about an analysis of data from the ORBIT-AF registry, in which patients with atrial fibrillation who were taking oral anticoagulation and aspirin had a higher risk of bleeding than patients on anticoagulation only.

---

September 1st, 2013

Is It Time to RE-ALIGN Our Thinking About Direct Thrombin Inhibitors?

Judith Andersen, AB, MD

Reflecting on the RE-ALIGN trial of dabigatran, Judith Andersen muses on the mechanisms of direct thrombin inhibitors.

---

September 1st, 2013

Positive Results for Edoxaban in VTE/PE

Larry Husten, PHD

Findings from the Hokusai-VTE trial of edoxaban

---

September 1st, 2013

Disappointing Results with Dabigatran for Mechanical Valves

Larry Husten, PHD

For more of our ESC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. Despite being more durable than bioprosthetic valves, mechanical heart valves are often not chosen because of the requirement for lifelong […]

---

August 29th, 2013

Statins Reduce Cardiovascular Events in Elders Without Established CVD

Nicholas Downing, MD

Statins are associated with lower risks for myocardial infarction and stroke among elders without established cardiovascular disease, according to a meta-analysis in the Journal of the American College of Cardiology. The analysis included eight randomized, placebo-controlled trials comprising nearly 25,000 patients aged 65 and older without CVD at baseline. During 3.5 years’ follow-up, statin use was […]

---

August 28th, 2013

American Heart Association Announces Late-Breaking Clinical Trials

Larry Husten, PHD

There are still a few days left in August, and the European Society of Cardiology meeting doesn’t start until this weekend in Amsterdam. Nevertheless, the American Heart Association has released the list of late-breaking clinical trials for its annual meeting in November. Late-Breaking Clinical Trials 1: Acute Cardiovascular and Cerebrovascular Care Sunday, Nov 17, 2013, 4:00 PM – 5:19 PM […]

---

July 1st, 2013

New Anticoagulant Found Safe and Effective in Acute Venous Thromboembolism

Larry Husten, PHD

In a large clinical trial the new oral anticoagulant apixaban (Eliquis, Pfizer and Bristol-Myers Squibb) was at least as effective as standard therapy and caused fewer bleeding complications in patients with acute venous thromboembolism (VTE). The results of the AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy) trial are being presented today at […]

---

June 28th, 2013

FDA Turns Back New Indication for Rivaroxaban to Prevent Stent Thrombosis in ACS Patients

Larry Husten, PHD

Johnson & Johnson said today that it had received a complete response letter from the FDA for the supplemental new drug application (sNDA) for rivaroxaban (Xarelto) for the prevention of stent thrombosis in patients with acute coronary syndromes (ACS). Earlier this year the FDA turned down for the second time the sNDA for the  general use of […]

---

June 24th, 2013

Roller Coaster Path to Approval for Eliquis Uncovered by FDA Documents

Larry Husten, PHD

After the presentation and publication of the pivotal ARISTOTLE trial,  the novel anticoagulant apixaban (Eliquis, Pfizer and Bristol-Myers Squibb) was widely expected to be  a blockbuster. But then it got bogged down at the FDA where initial hopes for a speedy approval were dashed after highly critical reviews. Approval of the drug was delayed for 9 months […]

---